LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Akciju saraksts・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

24.41 -0.89

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

24.2

Max

24.62

Galvenie mērījumi
By Trading Economics
Ienākumi	45M 72M
Pārdošana	14M 279M
P/E Sektora vidējais	15.955 108.767
EPS	0.42
Peļņas marža	25.761
Darbinieki	653
EBITDA	7.3M 48M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+32.61% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	410M 4.2B
Iepriekšējā atvēršanas cena	25.3
Iepriekšējā slēgšanas cena	24.41

Ziņu noskaņojums

By Acuity

34%

66%

79 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

14.845 / N/A Atbalsts un pretestība

ACADIA Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. marts 23:35 UTC

Galvenie ziņu notikumi

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

2026. g. 1. marts 23:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

2026. g. 1. marts 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

2026. g. 1. marts 23:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

2026. g. 1. marts 23:39 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 1. marts 23:39 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

2026. g. 1. marts 23:36 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

2026. g. 1. marts 23:24 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 1. marts 23:24 UTC

Tirgus saruna

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

2026. g. 1. marts 23:21 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 1. marts 23:21 UTC

Tirgus saruna

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

2026. g. 1. marts 23:19 UTC

Galvenie ziņu notikumi

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

2026. g. 1. marts 23:17 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

2026. g. 1. marts 23:14 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

2026. g. 1. marts 22:55 UTC

Galvenie ziņu notikumi

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

2026. g. 1. marts 22:54 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

2026. g. 1. marts 22:53 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

2026. g. 1. marts 22:38 UTC

Tirgus saruna

Galvenie ziņu notikumi

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

2026. g. 1. marts 22:21 UTC

Peļņas

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

2026. g. 1. marts 22:17 UTC

Tirgus saruna

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

2026. g. 1. marts 22:13 UTC

Tirgus saruna

Galvenie ziņu notikumi

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

2026. g. 1. marts 22:00 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

2026. g. 1. marts 21:40 UTC

Tirgus saruna

Galvenie ziņu notikumi

Spot Gold Up as Investors Shield Against Risk -- Market Talk

2026. g. 1. marts 21:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

2026. g. 1. marts 21:30 UTC

Tirgus saruna

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

2026. g. 1. marts 21:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

2026. g. 1. marts 21:19 UTC

Tirgus saruna

Galvenie ziņu notikumi

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

2026. g. 1. marts 20:58 UTC

Tirgus saruna

Galvenie ziņu notikumi

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

2026. g. 1. marts 20:40 UTC

Tirgus saruna

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

2026. g. 1. marts 20:24 UTC

Tirgus saruna

Galvenie ziņu notikumi

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Salīdzinājums

Cenas izmaiņa

ACADIA Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

32.61% augšup

Prognoze 12 mēnešiem

Vidējais 32.57 USD 32.61%

Augstākais 40 USD

Zemākais 23 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi ACADIA Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

15 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 15 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam ACADIA Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

14.845 / N/AAtbalsts un pretestība

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

79 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.